ଏସ୍କେଟାମାଇନ

ଏସ୍କେଟାମାଇନ
Clinical data
Trade names	Ketanest, Spravato, Vesierra, others
Synonyms	Esketamine hydrochloride; (S)-Ketamine; S(+)-Ketamine; JNJ-54135419
AHFS/Drugs.com	monograph
MedlinePlus	a619017
data	US DailyMed: Esketamine;
Pregnancy; category	US: N (Not classified yet) ; ;
Dependence; liability	Low–moderate (physical); high (psychological)
Routes of; administration	Intranasal
Legal status
Legal status	AU: S8 (Controlled) ; UK: POM (Prescription only) ; US: Schedule III ; EU: Rx-only ; ℞ (Prescription only);
Identifiers
	IUPAC name (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone;
ECHA InfoCard	100.242.065
Chemical and physical data
Formula	C13H16ClNO
Molar mass	୨୩୭.୭୩ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN[C@](C1=C(Cl)C=CC=C1)(CCCC2)C2=O;
	InChI InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3/t13-/m0/s1 ; Key:YQEZLKZALYSWHR-ZDUSSCGKSA-N ;
(verify)

ଏସ୍କେଟାମାଇନ, ଏକ ବେପାର ନାମ ସ୍ପ୍ରାଭାଟୋ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଅବସାଦ ରୋଗ ଚିକିତ୍ସା-ବିରୋଧୀ ହେଲେ କିମ୍ବା ଅବସାଦ ନିମନ୍ତେ ଆତ୍ମହତ୍ୟା ପ୍ରବଣତା ହେଲେ ବ୍ୟବହୃତ ହୁଏ ।^[୧] ^[୫] ତଥାପି ଏହା କେଟାମିନ ଅପେକ୍ଷା କମ୍ ପ୍ରଭାବଶାଳୀ ମନେହୁଏ ।^[୬] ଏହା ନିଶ୍ଚେତକ ଏବଂ ଯନ୍ତ୍ରଣା ନିବାରଣ ପାଇଁ ମଧ୍ୟ ବ୍ୟବହୃତ ହୋଇପାରେ ।^[୭] ଏହା ଏକ ନାକ ସ୍ପ୍ରେ କିମ୍ବା ଶିରାଭ୍ୟନ୍ତର ଇଞ୍ଜେକ୍ସନ ଭାବରେ ବ୍ୟବହୃତ ହୁଏ ।^[୧] ^[୭] ଅବସାଦ ରୋଗରେ ଏହି ଔଷଧ ଯୋଗୁ ଉପକାର ସାଧାରଣତଃ ୨୪ ଘଣ୍ଟା ମଧ୍ୟରେ ହୋଇଥାଏ ।^[୧]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ବିଯୋଡ଼, ମୁଣ୍ଡ ବୁଲାଇବା, ମୁଣ୍ଡବିନ୍ଧା, ଉଦ୍‌ବେଗ, ବାନ୍ତି ଏବଂ ରକ୍ତଚାପ ବୃଦ୍ଧି ହୋଇପାରେ ।^[୧] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅପବ୍ୟବ‌ହାର ହୋଇପାରେ ।^[୫] ଏହି ଯୌଗିକ ହେଉଛି କେଟାମାଇନର ଏସ (+) ଏନାନ୍ସିଓମର ।^[୮] ସ୍ତନ୍ୟପାନ କରାଯାଉ ନଥିବା ସମୟରେ ବ୍ୟବହାର କରିବାକୁ ପରାମର୍ଶ ଦିଆଯାଏ ।^[୯] ଏହା ମୁଖ୍ୟତଃ ଏହା ଏନ-ମିଥାଇଲ-ଡି-ଆସ୍ପାର୍ଟେଟ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ।^[୧]

୧୯୯୭ ମସିହାରେ ଜର୍ମାନୀରେ ଏସ୍କଟାମାଇନ୍ ଚିକିତ୍ସା ପାଇଁ ପ୍ରଥମେ ବ୍ୟବହୃତ ହୋଇଥିଲା ।^[୧୦] ^[୧୧] ୨୦୧୯ରେ ଆମେରିକା ଏବଂ ୟୁରୋପରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ଏହା ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୮] ^[୧୨] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ ।^[୧୩] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୧ ମସିହାରୁ ଚିକିତ୍ସାର ପ୍ରଥମ ମାସ ପାଇଁ ନାକ ସ୍ପ୍ରେର ମୂଲ୍ୟ ପ୍ରାୟ ୫,୫୦୦ରୁ ୭,୯୦୦ ଡଲାର ଅଟେ। ^[୧୪] ^[୫] ଯୁକ୍ତରାଜ୍ୟରେ ୫୦ ମିଗ୍ରା ଥିବା ୧୦ ଭାଏଲର ମୂଲ୍ୟ ପ୍ରାୟ ୨୬ ପାଉଣ୍ଡ । ^[୭]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ "Esketamine Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 23 January 2021. Retrieved 23 July 2021.
↑ "Spravato EPAR". European Medicines Agency (EMA). 16 October 2019. Archived from the original on 23 November 2020. Retrieved 24 November 2020.
↑ "Spravato 28 mg nasal spray, solution - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 28 August 2021. Retrieved 24 November 2020.
↑ "Vesierra 25 mg/ml solution for injection/infusion - Summary of Product Characteristics (SmPC)". (emc). 21 February 2020. Archived from the original on 21 April 2021. Retrieved 24 November 2020.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ "Spravato- esketamine hydrochloride solution". DailyMed. 6 August 2020. Archived from the original on 18 March 2021. Retrieved 26 September 2020.
↑ Bahji, A; Vazquez, GH; Zarate CA, Jr (15 February 2021). "Erratum to "Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis" [Journal of Affective Disorders 278C (2021) 542-555]". Journal of affective disorders. 281: 1001. doi:10.1016/j.jad.2020.11.103. PMID 33229028.
↑ ^୭.୦ ^୭.୧ ^୭.୨ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1411. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
↑ ^୮.୦ ^୮.୧ Commissioner, Office of the (24 March 2020). "FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic". FDA (in ଇଂରାଜୀ). Archived from the original on 23 July 2021. Retrieved 23 July 2021.
↑ "Esketamine". Drugs and Lactation Database (LactMed) [Internet]. 2019. PMID 31038855.
↑ Roche, Victoria; Zito, William S.; Lemke, Thomas; Williams, David A. (29 July 2019). Foye's Principles of Medicinal Chemistry (in ଇଂରାଜୀ). Lippincott Williams & Wilkins. p. PT1423. ISBN 978-1-4963-8587-1. Archived from the original on 28 August 2021. Retrieved 23 July 2021.
↑ Himmelseher S, Pfenninger E (December 1998). "[The clinical use of S-(+)-ketamine--a determination of its place]". Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie. 33 (12): 764–70. doi:10.1055/s-2007-994851. PMID 9893910.
↑ "Spravato". Archived from the original on 23 November 2020. Retrieved 23 July 2021.
↑ Ferrier, I. Nicol; Waite, Jonathan (4 July 2019). The ECT Handbook (in ଇଂରାଜୀ). Cambridge University Press. p. 150. ISBN 978-1-911623-16-8. Archived from the original on 29 August 2021. Retrieved 23 July 2021.
↑ "Spravato Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 12 November 2020. Retrieved 23 July 2021.

[AHFS2021-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ "Esketamine Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 23 January 2021. Retrieved 23 July 2021.

[Spravato_EPAR-2] "Spravato EPAR". European Medicines Agency (EMA). 16 October 2019. Archived from the original on 23 November 2020. Retrieved 24 November 2020.

[3] "Spravato 28 mg nasal spray, solution - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 28 August 2021. Retrieved 24 November 2020.

[4] "Vesierra 25 mg/ml solution for injection/infusion - Summary of Product Characteristics (SmPC)". (emc). 21 February 2020. Archived from the original on 21 April 2021. Retrieved 24 November 2020.

[PI2020-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ "Spravato- esketamine hydrochloride solution". DailyMed. 6 August 2020. Archived from the original on 18 March 2021. Retrieved 26 September 2020.

[6] Bahji, A; Vazquez, GH; Zarate CA, Jr (15 February 2021). "Erratum to "Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis" [Journal of Affective Disorders 278C (2021) 542-555]". Journal of affective disorders. 281: 1001. doi:10.1016/j.jad.2020.11.103. PMID 33229028.

[BNF80-7] ୭.୦ ^୭.୧ ^୭.୨ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1411. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[FDA2019-8] ୮.୦ ^୮.୧ Commissioner, Office of the (24 March 2020). "FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic". FDA (in ଇଂରାଜୀ). Archived from the original on 23 July 2021. Retrieved 23 July 2021.

[Lac2019-9] "Esketamine". Drugs and Lactation Database (LactMed) [Internet]. 2019. PMID 31038855.

[10] Roche, Victoria; Zito, William S.; Lemke, Thomas; Williams, David A. (29 July 2019). Foye's Principles of Medicinal Chemistry (in ଇଂରାଜୀ). Lippincott Williams & Wilkins. p. PT1423. ISBN 978-1-4963-8587-1. Archived from the original on 28 August 2021. Retrieved 23 July 2021.

[Him1998-11] Himmelseher S, Pfenninger E (December 1998). "[The clinical use of S-(+)-ketamine--a determination of its place]". Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie. 33 (12): 764–70. doi:10.1055/s-2007-994851. PMID 9893910.

[EMA2021-12] "Spravato". Archived from the original on 23 November 2020. Retrieved 23 July 2021.

[13] Ferrier, I. Nicol; Waite, Jonathan (4 July 2019). The ECT Handbook (in ଇଂରାଜୀ). Cambridge University Press. p. 150. ISBN 978-1-911623-16-8. Archived from the original on 29 August 2021. Retrieved 23 July 2021.

[14] "Spravato Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 12 November 2020. Retrieved 23 July 2021.

[୧]

[୩]

[୪]

[୫]

[୨]

[୬]

[୭]

[୮]

[୯]

[୧୦]

[୧୧]

[୧୨]

[୧୩]

[୧୪]